Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have been given a consensus recommendation of “Moderate Buy” by the fourteen ratings firms that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $24.50.

KURA has been the topic of several research analyst reports. Wall Street Zen cut shares of Kura Oncology from a “buy” rating to a “hold” rating in a report on Friday, May 2nd. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Kura Oncology in a report on Friday, June 20th. Barclays decreased their price target on shares of Kura Oncology from $32.00 to $11.00 and set an “overweight” rating on the stock in a report on Friday, May 2nd. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Kura Oncology in a research note on Monday, April 28th. Finally, UBS Group reduced their target price on Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th.

Kura Oncology Trading Down 1.0%

Kura Oncology stock opened at $5.67 on Monday. The stock has a market cap of $490.85 million, a P/E ratio of -2.70 and a beta of 0.40. Kura Oncology has a fifty-two week low of $5.41 and a fifty-two week high of $23.48. The firm’s fifty day moving average price is $6.17 and its 200-day moving average price is $7.18. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.07 and a current ratio of 8.07.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The firm had revenue of $14.11 million for the quarter, compared to analysts’ expectations of $39.08 million. Equities research analysts forecast that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. State of Wyoming bought a new position in shares of Kura Oncology during the first quarter valued at about $48,000. Virtus ETF Advisers LLC grew its stake in shares of Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after purchasing an additional 3,061 shares during the last quarter. Pallas Capital Advisors LLC bought a new stake in shares of Kura Oncology in the first quarter worth about $66,000. Flower City Capital bought a new stake in shares of Kura Oncology in the first quarter worth about $79,000. Finally, Magnetar Financial LLC bought a new stake in shares of Kura Oncology in the first quarter worth about $79,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.